0000000000982632

AUTHOR

Aneta Kowal

0000-0002-5785-2330

showing 2 related works from this author

Fusion of the 1H NMR data of serum, urine and exhaled breath condensate in order to discriminate chronic obstructive pulmonary disease and obstructiv…

2015

Chronic obstructive pulmonary disease, COPD, affects the condition of the entire human organism and causes multiple comorbidities. Pathological lung changes lead to quantitative changes in the composition of the metabolites in different body fluids. The obstructive sleep apnea syndrome, OSAS, occurs in conjunction with chronic obstructive pulmonary disease in about 10–20 % of individuals who have COPD. Both conditions share the same comorbidities and this makes differentiating them difficult. The aim of this study was to investigate whether it is possible to diagnose a patient with either COPD or the OSA syndrome using a set of selected metabolites and to determine whether the metabolites t…

medicine.medical_specialtyPathology(COPD)Endocrinology Diabetes and MetabolismMetaboliteClinical BiochemistryChronic obstructive pulmonary disease (COPD)Urinediscriminant modelsBiochemistryGastroenterologychronic obstructive pulmonary diseasechemistry.chemical_compoundNMR spectroscopyInternal medicinePartial least squares regressionMedicineExhaled breath condensatePathologicalCOPDLungbusiness.industrymedicine.diseasechemometricsrespiratory tract diseasesObstructive sleep apneamedicine.anatomical_structurechemistrybusinessobstructive sleep apnea syndrome (OSAS)Metabolomics
researchProduct

Metabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary disease

2014

Chronic obstructive pulmonary disease (COPD) and lung cancer are widespread lung diseases. Cigarette smoking is a high risk factor for both the diseases. COPD may increase the risk of developing lung cancer. Thus, it is crucial to be able to distinguish between these two pathological states, especially considering the early stages of lung cancer. Novel diagnostic and monitoring tools are required to properly determine lung cancer progression because this information directly impacts the type of the treatment prescribed. In this study, serum samples collected from 22 COPD and 77 lung cancer (TNM stages I, II, III, and IV) patients were analyzed. Then, a collection of NMR metabolic fingerprin…

AdultMaleOncologymedicine.medical_specialtyLung NeoplasmsMagnetic Resonance SpectroscopyClinical BiochemistryPharmaceutical ScienceCreatineAnalytical ChemistryDiagnosis DifferentialPulmonary Disease Chronic Obstructivechemistry.chemical_compoundPredictive Value of TestsCarcinoma Non-Small-Cell LungInternal medicineDrug DiscoveryBiomarkers TumormedicineHumansMetabolomicsLeast-Squares AnalysisRisk factorLung cancerLungPathologicalEarly Detection of CancerSpectroscopyAgedNeoplasm StagingAged 80 and overUnivariate analysisCOPDLungChemistryDiscriminant AnalysisMiddle AgedPrognosismedicine.diseaserespiratory tract diseasesmedicine.anatomical_structureMultivariate AnalysisDisease ProgressionFemaleLung cancer stagingJournal of Pharmaceutical and Biomedical Analysis
researchProduct